Tags

Type your tag names separated by a space and hit enter

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    1Memorial Sloan Kettering Cancer Center.

    ,

    2Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

    ,

    3Massachusetts General Hospital Cancer Center.

    ,

    4Stanford Cancer Institute.

    ,

    5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

    ,

    6Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

    ,

    7University of Wisconsin Carbone Cancer Center.

    ,

    8Moffitt Cancer Center.

    ,

    9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

    ,

    10The University of Texas MD Anderson Cancer Center.

    ,

    11Huntsman Cancer Institute at the University of Utah.

    ,

    12Mayo Clinic Cancer Center.

    ,

    3Massachusetts General Hospital Cancer Center.

    ,

    13Roswell Park Comprehensive Cancer Center.

    ,

    14University of Michigan Rogel Cancer Center.

    ,

    15Duke Cancer Institute.

    ,

    16Fox Chase Cancer Center.

    ,

    17Consultant.

    ,

    18Dana-Farber/Brigham and Women's Cancer Center.

    ,

    19O'Neal Comprehensive Cancer Center at UAB.

    ,

    20City of Hope National Medical Center.

    ,

    21University of Colorado Cancer Center.

    ,

    22Vanderbilt-Ingram Cancer Center.

    ,

    23UC San Diego Moores Cancer Center.

    ,

    24Yale Cancer Center/Smilow Cancer Hospital.

    ,

    25University of Washington/Seattle Cancer Care Alliance.

    ,

    19O'Neal Comprehensive Cancer Center at UAB.

    ,

    26The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

    ,

    27Fred & Pamela Buffett Cancer Center; and.

    ,

    28National Comprehensive Cancer Network.

    28National Comprehensive Cancer Network.

    Source

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    31200358

    Citation

    Zelenetz, Andrew D., et al. "NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 17, no. 6, 2019, pp. 650-661.
    Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650-661.
    Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., ... Sundar, H. (2019). NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal of the National Comprehensive Cancer Network : JNCCN, 17(6), pp. 650-661. doi:10.6004/jnccn.2019.0029.
    Zelenetz AD, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. PubMed PMID: 31200358.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. AU - Zelenetz,Andrew D, AU - Gordon,Leo I, AU - Abramson,Jeremy S, AU - Advani,Ranjana H, AU - Bartlett,Nancy L, AU - Caimi,Paolo F, AU - Chang,Julie E, AU - Chavez,Julio C, AU - Christian,Beth, AU - Fayad,Luis E, AU - Glenn,Martha J, AU - Habermann,Thomas M, AU - Lee Harris,Nancy, AU - Hernandez-Ilizaliturri,Francisco, AU - Kaminski,Mark S, AU - Kelsey,Christopher R, AU - Khan,Nadia, AU - Krivacic,Susan, AU - LaCasce,Ann S, AU - Mehta,Amitkumar, AU - Nademanee,Auayporn, AU - Rabinovitch,Rachel, AU - Reddy,Nishitha, AU - Reid,Erin, AU - Roberts,Kenneth B, AU - Smith,Stephen D, AU - Snyder,Erin D, AU - Swinnen,Lode J, AU - Vose,Julie M, AU - Dwyer,Mary A, AU - Sundar,Hema, PY - 2019/6/15/entrez PY - 2019/6/15/pubmed PY - 2019/6/15/medline SP - 650 EP - 661 JF - Journal of the National Comprehensive Cancer Network : JNCCN JO - J Natl Compr Canc Netw VL - 17 IS - 6 N2 - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL. SN - 1540-1413 UR - https://www.unboundmedicine.com/medline/citation/31200358/NCCN_Guidelines_Insights:_B-Cell_Lymphomas,_Version_3.2019 L2 - https://jnccn.org/doi/10.6004/jnccn.2019.0029 DB - PRIME DP - Unbound Medicine ER -